-
Mashup Score: 3A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma - 2 month(s) ago
This pilot study explored whether using immunotherapy drugs in combination with locoregional therapies for patients with non-metastatic hepatocellular carcinoma
Source: academic.oup.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 8
This study retrospectively reviewed the outcomes of patients with advanced hepatocellular carcinoma receiving atezolizumab with bevacizumab (A + B) therapy at t
Source: academic.oup.comCategories: General Medicine News, Onc News and JournalsTweet-
'@MunafAlkadimi et al show real-world outcomes for pts w/ #HCC undergoing atezo+bev for 1st-line treatment. #PFS was similar to IMBRAVE 150; reduced #OS was attributed to older adult & nonWhite pts w/ moderate liver dysfunction. @DrSukeshiArora @doczohra1 https://t.co/bJT2RqvMYA https://t.co/P0pDLV8sFK
-
-
Mashup Score: 3Rural-Urban Disparities in Colorectal Cancer Screening, Diagnosis, Treatment, and Survivorship Care: A Systematic Review and Meta-Analysis - 3 month(s) ago
This article evaluates the literature on differences in colorectal cancer screening, stage at diagnosis, treatment, and survivorship care of patients in rural a
Source: academic.oup.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 71Consuming Patients’ Days: Time Spent on Ambulatory Appointments by People With Cancer - 3 month(s) ago
This study used real-time location system and geolocation data to assess how much time (in minutes) patients spent on attending clinic appointments. Even seemin
Source: academic.oup.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial - 3 month(s) ago
In the ARASENS trial, darolutamide in combination with androgen-deprivation therapy (ADT) and docetaxel significantly reduced the risk of death compared with pl
Source: academic.oup.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5Combined RAF and MEK Inhibition to Treat Activated Non-V600 BRAF-Altered Advanced Cancers - 3 month(s) ago
Cancers with non-V600 BRAF-activating alterations have no matched therapy. This study focused on whether combined RAF plus higher dose MEK inhibition would inhi
Source: academic.oup.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4Immune-Related Adverse Event Likelihood Score Identifies “Pure” IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population - 3 month(s) ago
This article describes a set of clinical criteria, the IRAE likelihood score (ILS) that allow for distinguishing between immunotherapy-elicited, truly immune-me
Source: academic.oup.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3
This study aimed to determine the pan-cancer landscape of MUTYH alterations and the relationship between MUTYH mutations and potentially actionable biomarkers,
Source: academic.oup.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 7A Feasibility Study Investigating an Exercise Program in Metastatic Cancer Based on the Patient-Preferred Delivery Mode - 3 month(s) ago
This study aimed to determine the feasibility and preliminary efficacy of an exercise intervention based on a patient-preferred delivery mode in patients affect
Source: academic.oup.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 8The Oncologist - 4 month(s) ago
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.
Source: academic.oup.comCategories: General Medicine News, Onc News and JournalsTweet
'@AshwinSomasund1 & colleagues describe HCRN GI15-225 as a multicenter single-arm study assessing combination pembrolizumab #IO + Y90 local therapy for poor risk #HCC. >50% of pts had disease control at 6mo w/ median #PFS of nearly 10mo. @DocSacher https://t.co/nWTXYQs4dl https://t.co/2O7snKrnZJ